Showing results (1061-1070 of 1,170) with videos related to

Sort By:
Pageof 117
Evidence-Based Complementary and Alternative Medicine : Ecam|July 25, 2022
Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical TrialTarek Hassanein, Dean Tai, Chenghai Liu, et al.
Nature|December 18, 2015
Spatial and temporal distribution of mass loss from the Greenland Ice Sheet since AD 1900Kristian K Kjeldsen, Niels J Korsgaard, Anders A Bjørk, et al.
Current Oncology (Toronto, Ont.)|May 15, 2023
Consensus Recommendations to Optimize the Detection and Reporting of NTRK Gene Fusions by RNA-Based Next-Generation SequencingTracy L Stockley, Bryan Lo, Adrian Box, et al.
Cellular and Molecular Gastroenterology and Hepatology|August 14, 2025
CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Alcoholic PancreatitisSupriya Srinivasan, Siddharth Mehra, Sudhakar Jinka, et al.
Journal of Medicinal Chemistry|October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitorsMichael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 21, 2007
Plexin-B1 mutations in prostate cancerOscar Gee-Wan Wong, Tharani Nitkunan, Izumi Oinuma, et al.
Cell|October 15, 2013
A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selectionJorge Zeron-Medina, Xuting Wang, Emmanouela Repapi, et al.
Scientific Data|March 19, 2026
OzBarley: A genetic and phenotypic data resource capturing the Australian barley breeding historyUte Baumann, Elena Kalashyan, Julian Schwerdt, et al.
Journal for Immunotherapy of Cancer|March 28, 2025
SITC strategic vision: prevention, premalignant immunity, host and environmental factorsSasha E Stanton, Kristin G Anderson, Tullia C Bruno, et al.
Hepatology (Baltimore, Md.)|August 4, 2026
Nucleos(t)ide withdrawal vs Nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B Trial)Mark Thursz, Maud Lemoine, Ashley Brown, et al.
Pageof 117